Harvard Business Review

MARCH 2, 2011

The days when you could make a living responding to companies' discovery of strategy, as in "Gosh, we gotta get ourselves one of those," are gone with the 1970s (or maybe the 1990s in the "developing world"). Strategy has triumphed, the installed base is huge, no self-respecting company would be without one.

Consultative 15

Consultative Strategy McKinsey Porter 15

QAspire

JANUARY 24, 2010

He was a marketing executive with a large pharmaceutical company when he decided to pursue his calling and start a fitness center. “ You get almost nothing without going through some kind of pain, unless you win a lottery.”, replied the man who was himself a fitness freak. He neither had space nor money to start out.

Directory 84

Directory Blog Pharmaceuticals Quality 84

Harvard Business Review

AUGUST 17, 2012

You could argue that Cipla's formula is simply to piggyback on other companies' products, so it doesn't have to pay for R&D. In the US, Cipla sells its products generic pharmaceutical companies such as Teva and Eagle. irketi in 2011 provided expansion in Turkey. Cipla is not a stranger to M&A either. laç Ticaret Anonim ?irketi

Company 11

Company Pharmaceuticals Business Model Fixed Costs 11

The Recovering Engineer

FEBRUARY 27, 2010

I am not a doctor, pharmacist, attorney, drug company executive or any other person who has deep insights into the intricacies of our health care system. As I look at the health care reform debate, I see a number of these behaviors in the way the discussion(s) is (are) proceeding. And, frankly, it makes me sick.

Health Care 102

Health Care Engineering System Politics 102

The Recovering Engineer

FEBRUARY 27, 2010

I am not a doctor, pharmacist, attorney, drug company executive or any other person who has deep insights into the intricacies of our health care system. As I look at the health care reform debate, I see a number of these behaviors in the way the discussion(s) is (are) proceeding. And, frankly, it makes me sick.

Health Care 102

Health Care Engineering System Politics 102

Harvard Business Review

AUGUST 3, 2012

Over the past decade, though, big pharma has slowly but surely made a break with this tradition as companies moved away from the old self-contained integrated model into far more open and flexible networked models. if you want to work with the best people, you're going to have go outside your own company".

Licensing 13

Licensing Depreciation Pharmaceuticals Budgeting 13

Harvard Business Review

MAY 20, 2014

The rate of business formation in 2011 was almost half of what it was in 1978, with the rate of dissolution somewhat higher than the past couple decades. In pharmaceuticals, the largest company, Pfizer, is the result of decades of mergers. Consolidation of the financial sector has led to similar dynamics in other industries.

Pharmaceuticals 10

Pharmaceuticals Banking Chemicals Trends 10

Harvard Business Review

APRIL 16, 2014

That is perhaps the most frequent question I’ve received since 2011 when GlaxoSmithKline changed the link between the bonus pay of our pharmaceutical sales professionals in the United States and the numbers of prescription sold for a particular medicine. I watch the sales numbers and I’m concerned if they dip.

Incentives 13

Incentives Pharmaceuticals Health Care Metrics 13

Strategy Driven

MARCH 18, 2011

The conventional wisdom about strategy may be leading your company astray. Achieving coherence requires a sharpness of focus that few companies have mastered. In this unpredictable economy, traditional approaches to strategy are a luxury most companies cannot afford. by Paul Leinwand and Cesare Mainardi. Let’s go after it.”

Resources 53

Resources Industry System Strategy 53

Harvard Business Review

DECEMBER 20, 2011

The two biggest product stories of 2011 were arguably Lipitor and the iPhone 4S. Throughout its history, Pfizer's biggest product and the biggest-selling branded drug in pharmaceutical industry history, has delivered some confounding strategic lessons. 30) of a blockbuster prescription drug. Lipitor's Long Good-bye.

Disintermediation 15

Disintermediation Industry Pharmaceuticals Price 15

Harvard Business Review

NOVEMBER 8, 2017

The rising flood of hardware, pharmaceuticals, and technical expertise from American manufacturers and hospital companies, which is connected to the needs of a growing number of hospitals, is also pushing many systems closer to the U.S. Over the same period, pharmaceutical exports have doubled. Transforming Health Care.

Health Care 8

Health Care Tourism Pharmaceuticals Cost 8

Harvard Business Review

JANUARY 12, 2011

A few years ago, pharmaceutical giant sanofi-aventis sponsored an anonymous, Web-based survey of 4,200 workers at four health care, transportation, and manufacturing companies. Across the four companies, sleep-related reductions in productivity cost $54 million a year. Results from a survey of employees at several large U.S.

Cost 15

Cost Absenteeism Pharmaceuticals Survey 15

Harvard Business Review

JANUARY 26, 2011

On January 25, the South African Institute of Chartered Accountants held a press conference to call attention to a new framework for integrated reporting (reporting sustainability information alongside financial information in companies' filings). Daniela Saltzman is an MBA student at HBS, class of 2011. Stay tuned.

Long-term 14

Long-term Sample Report Pharmaceuticals 14

Harvard Business Review

FEBRUARY 15, 2012

Some are shutting down because the companies that own them are going bankrupt, while other corporations are moving inland. While Guangdong's exports accounted for as much as 37% of China's exports by 2000, its share dropped to 28% in 2011. Look at the data.

GDP 12

GDP Pharmaceuticals Long-term Globalization 12

Harvard Business Review

MARCH 2, 2012

As global companies focus their strategies on developed and emerging markets, they require substantial cadres of leaders capable of operating effectively anywhere in the world. American companies and academic institutions possess unique competitive advantages in developing these global leaders.

Competitive Advantage 13

Competitive Advantage Globalization Development Intellectual Capital 13

Harvard Business Review

JUNE 29, 2015

To get a better picture of this trend, Stiebale, along with Kevin Amess from Nottingham University Business School and Mike Wright from Imperial College Business School, analyzed hundreds of PE-backed LBOs of UK companies from 1998 to 2008. Maybe you remember how savagely the industry was portrayed during the 2012 U.S. election?

LBO 8

LBO Innovation Sample Short-term 8

Harvard Business Review

DECEMBER 14, 2015

” For example, one of Berlin’s clients, a Fortune 25 company, has integrated mindfulness techniques into its high potentials program with the goal of creating agile and flexible mindsets as a foundation for leadership. “In the aftermath of 9/11, the employees at my company were noticeably shaky and distracted.

CEO 8

CEO Emotional Intelligence Cooper Pharmaceuticals 8

In the CEO Afterlife

JUNE 19, 2011

by John • June 19, 2011 • Life , Marketing , Strategy • 1 Comment. So do pharmaceutical giants Eli Lilly and Pfizer. June 21, 2011 at 5:57 pm. The “M” Word: A Company’s Most Underrated Intangible. December 2011. November 2011. October 2011. September 2011.

Advice 147

Advice Marketing Marketing Strategy Brand 147

Harvard Business Review

FEBRUARY 24, 2015

There is little consensus as to whether firms that find themselves spun off from other companies – either as new, standalone companies, or under the stewardship of new parent companies – perform better or worse than they did before. Does the business have a complete, balanced, and cohesive management team?

Chemicals 8

Chemicals How To Kahneman Reputation 8

Harvard Business Review

MAY 17, 2012

Jane Chen, Linus Liang, Naganand Murty, and Rahul Panicker cofounded a company called Embrace to come up with an affordable infant warmer for use in developing countries — one that costs far less than incubators available in the West. In 2011, Embrace piloted the product in India, where 1.2

Incubator 11

Incubator Business Model Entrepreneur Cost 11

Harvard Business Review

OCTOBER 3, 2013

Take Citrus Lane CEO Mauria Finley, whose company was experiencing some growing pains, appropriately enough; the startup sends monthly packages of great baby products to moms. Back in 2011, in Citrus Lane’s first six months, its small founding team worked in a house and ate lunch together every day around a big table. After raising $5.1

Pharmaceuticals 8

Pharmaceuticals Seminar Learning-by-Doing Open-book 8

Strategy Driven

JANUARY 24, 2011

StrategyDriven effective executives, efficient employees Home About The StrategyDriven Organization Our Company Our Contributors Karen K. What did 2010 look like for you and your company? But there’s only one that really matters: Did your company effectively execute its plans and initiatives? Juliano Howard T. Dickens Jr.

Execution 68

Execution Company 360-Degree Feedback Cooper 68

Harvard Business Review

SEPTEMBER 5, 2013

When we interviewed 45 such people across 39 companies in 8 industries in the United States and Europe, we found that by identifying low-value tasks to either drop completely, delegate to someone else or outsource, the average worker gained back roughly one day a week they could use for more important tasks.

Productivity 8

Productivity Products Peer Review Short-term 8

Harvard Business Review

JUNE 16, 2016

The initial breakthrough came in 1987, but the first drug wasn’t approved until 2011. Profit-driven companies, on the other hand, feel so much pressure to go to market that they often pass on ideas with vast potential. Draetta of IACS has found many of the same issues arise in pharmaceutical research.

Technology 8

Technology Venture Capitalist Supply Chain Innovation 8

Harvard Business Review

SEPTEMBER 14, 2011

We recently visited the brand-new R&D lab of Dr Reddy's , one of India's leading pharmaceutical firms. In 2008, Dr Reddy's acquired Chirotech, Dow Chemical's R&D unit, for $32 million, and in April 2011 relocated it to a new 33,000 sq. Is your company globalizing R&D? Cambridge, U.K. facility in Cambridge Science Park.

Globalization 9

Globalization Innovation Decentralization Chemicals 9

Eric Jacobson

JUNE 8, 2010

In its heyday, Marion had 3,400 employees with sales of nearly $1 billion and in 1989 merged with Merrell Dow Pharmaceuticals. The Kansas City Star newspaper recently featured a story about Marion Laboratories and its 60th anniversary. "Great Places To Work" Employee Perks New Book Shows You How To Set A Goal And Then Reac.

Mentor 56

Mentor Mission Statement Tips Open-book 56

Harvard Business Review

NOVEMBER 2, 2018

Workers’ increasing out-of-pocket costs are creating widespread discontent with the underlying costs of care — a problem largely driven by the high prices charged to private payers for health services and pharmaceuticals. Between 2011 and 2017, employees’ premiums and deductibles grew faster than their median income.

Health Care 8

Health Care Cost Insurance Price 8

Harvard Business Review

NOVEMBER 20, 2015

Compliance is crucial for pharmaceutical makers such as Abbott and Amgen – a “ Form 483 ” warning from an FDA inspector can shut down a drug facility in an instant and even land top executives in jail. Jorge Rodriguez-Gonzalez, founder of PACIV in Puerto Rico, flipped this dynamic on its head.

Supply Chain 8

Supply Chain Collins Golden Handcuff Pharmaceuticals 8

Harvard Business Review

MAY 10, 2013

Investors in publicly traded companies are understood to desire stable, predictable earnings and growth. The problems with public markets and quarter-by-quarter thinking are many, but for companies in fast-changing environments the biggest issue is that public markets are not patient — miss a quarter and the punishment can be severe.

Venture Capitalist 8

Venture Capitalist Restructuring Competitive Advantage Short-term 8

Harvard Business Review

NOVEMBER 21, 2013

Wyeth, a pharmaceutical acquired by Pfizer in 2009, was the sole supplier of Premarin. Why do some companies choose to patent their innovation while others choose to hide it? Coca Cola could have patented the formula, but that would only give the company twenty years of exclusivity rights to their classic taste.

Intangible Assets 8

Intangible Assets Merchandising Innovation Pharmaceuticals 8

Harvard Business Review

JUNE 21, 2017

We decided to create a direct-to-patient initiative using Collective Impact, a framework for tackling social issues first articulated , in 2011, by John Kania and Mark Kramer. To this end, we set forth and executed a plan to adopt best practices from leading direct-to-consumer companies in the areas of customer acquisition and retention.

Metrics 8

Metrics Health Care Learning-by-Doing Education 8

Harvard Business Review

SEPTEMBER 11, 2014

For example, insurance companies face technological uncertainty that comes from how big data and analytics investments will drive revenue; whereas demand is based on highly predictable demographics. Companies that excel at resolving technological uncertainty often develop a broader technology palette.

Uncertainty 22

Uncertainty Industry Bottom-up Technology 22

Harvard Business Review

MAY 25, 2017

Indeed, the profusion of new treatments may present a serious challenge to the current payer strategy of negotiating favorable pricing with drug and device companies. In 2011 81 digital health startups received venture funding; with consistent year-over-year increases, 296 startups were venture backed in 2016.

Health Care 9

Health Care Trends Venture Funding Technology 9

Harvard Business Review

DECEMBER 21, 2015

companies repatriate from abroad, from 35% to 10% or lower. That, he says, “would allow companies to reinvest the nontaxed portion in the United States, creating thousands of jobs.” From 2005 to 2014, 458 S&P 500 companies expended $3.7 These companies held much of the remaining 11.8%

Hedge 8

Hedge Proposal Pharmaceuticals Price 8